AzTrials
AzTrials

Peri-ImplantitisNCT06379022

Proteomic Analysis of Newly Restored Single Implants

An observational study of Peri-Implantitis and Peri-implant Mucositis, run by Aristotle University Of Thessaloniki at 1 site in Greece.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In 10 systemically healthy non-smokers, free of periodontitis, one newly restored implant (baseline-T0) and one corresponding tooth were followed over 12 months (T1). All implants were screw-retained, and platform-switched. Oral hygiene was closely monitored during the study. Read more about this study

Who is it for?
Ages 18 to 60 yearsHealthy volunteers can take part
How many people
10 participants
Where
1 siteGreece
Study dates
3 Dec 2018to 29 Nov 2019
How long will I take part?
12 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: Systemically healthy non-smokers, who were previously treated for periodontal disease and recently received implant therapy; Each subject contributed with one newly restored screw-retained implant 2-4 weeks following functional loading (baseline, T0) and was closely followed over 12 months (T1).

Who may be able to join

  • systemically healthy non-smokers having a single implant prosthetically restored (2-4 weeks).

Who cannot join

  • younger than 18 years of age, <18 teeth (excluding third molars), untreated periodontal disease, periodontitis Stage III-IV, evidence of peri-implantitis (Berglundh et al, 2018) at other implant sites, significant soft tissue pathology, untreated carious cavities (five or more), systemic diseases that require intake of medications, medical conditions that contraindicated surgical implant placement, the medication that interferes with bone metabolism, pregnancy or lactation, inadequate dimensions of the alveolar ridge or grafted bone at the surgical site, and tooth extraction 3 months prior to the study, smoking.

Trial locations and contacts

1 site in 1 country.

Greece1 site
  • Dental School, Aristotle University

    Thessaloniki, 54124

Other trials in Greece

About this study

Official title: Clinical and Cellular Responses of Tissues at Newly Restored Single Implants Compared to Contralateral Natural Teeth During Their First Year of Functional Loading

In 10 systemically healthy non-smokers, free of periodontitis, one newly restored implant (baseline-T0) and one corresponding tooth were followed over 12 months (T1). All implants were screw-retained, and platform-switched. Oral hygiene was closely monitored during the study. Probing pocket depth (PPD), attachment levels (CAL), bleeding and plaque indices and crevicular fluid were collected from an implant-site (PICF) and a tooth-site (GCF). Total proteomic profiles in PICF and GCF were investigated using label-free quantitative proteomics.

Read the detailed description

Study population A total of 10 systemically healthy non-smokers, who were previously treated for periodontal disease and received implant therapy, were recruited between December 2018 and November 2019. Each subject contributed with a newly restored screw-retained implant 2-4 weeks following functional loading (baseline, T0) and was closely followed over 12 months (T1). All study implants were platform-switched (ø4.1. Straumann® Bone Level) and were installed following a two-stage surgical placement protocol. A contralateral tooth in the same jaw, but on the opposite quadrant, served as the control. Implant placement was planned based on clinical and cone beam computerized tomography evaluations and was performed using a prosthetic guide. Implants were submerged and were exposed 6 months later when a healing abutment was adjusted on the fixture followed by a screw-retained crown 1 month later. Exclusion criteria included younger than 18 years of age, <18 teeth (excluding third molars), untreated periodontal disease, periodontitis Stage III-IV, evidence of peri-implantitis (Berglundh et al, 2018) at other implant sites, significant soft tissue pathology, untreated carious cavities (five or more), systemic diseases that require intake of medications, medical conditions that contraindicated surgical implant placement, the medication that interferes with bone metabolism, pregnancy or lactation, inadequate dimensions of the alveolar ridge or grafted bone at the surgical site, and tooth extraction 3 months prior to the study, smoking.

Clinical assessments Site-specific and full-mouth clinical indices were assessed at T0 and T1. Oral hygiene instructions using a manual toothbrush and the modified Bass technique were re-iterated at four time points over the 12-month study period (T0, 3-, 6-months and T1). Prophylaxis comprising supragingival ultrasonic debridement and polishing with a rubber cup was carried out at the same time points. In detail, the following site-specific clinical indices probing pocket depth (PPD), clinical attachment levels (CAL), recession (REC), modified gingival index (MGI) (score range 0-4) (Lobene et al. 1986), modified dental plaque index (mPI)1 (score range: 0-3) and modified sulcus bleeding index (mBI)1 (score range: 0-3) were determined at the mesial buccal site of the study implant in a similar manner as PPD, CAL, REC, MGI, plaque index (PI)2 (score range: 0-3) and sulcus bleeding index (SBI)3 (score range: 0-5) at the control tooth site. The width of keratinized tissues (KTW) was determined at the mid-buccal aspect of the test-implant/control tooth. Moreover, on a full-mouth basis PPD, CAL and dichotomous supragingival dental plaque (PI) (O'Leary et al., 1972) and bleeding on probing (BOP) (Ainamo et al., 1975) were recorded at six sites per tooth/implant present in the mouth. Periodontal clinical indices were determined using a manual periodontal probe (PCP-UNC 15; Hu-Friedy XP-23/QW, Hu-Friedy, Chicago, IL, USA) to the nearest millimeter.

Radiographic examination The VixWin™ Platinum Gendex software (Hatfield, PA, USA) linearly assessed the distance between the implant platform and the bone crest (I-BC) parallel to the long axis of the implant fixture at T0 and T1 on intra-oral digital radiographs. Periapical digital radiographs (RadioVisioGraphy; Trophy Radiology S.A., Paris, France) were obtained using the long cone paralleling technique at a 10 cm distance between the x-ray head and the digital sensor.

Collection of crevicular fluid samples Peri-implant crevicular fluid (PICF) was collected from the mesial-buccal site of the newly restored study implant, while gingival crevicular fluid (GCF) was collected from the mesial-buccal site of a contralateral control tooth at T0 and T1. Before PICF/GCF collection, the surfaces were gently air-dried and isolated from saliva by placing cotton rolls and using a saliva ejector. Then, supragingival plaque was carefully removed by sterile curettes and paper strips (Periopaper, OraFlow Inc., Smithtown, NY, USA) were gently placed in the mesial aspect of the peri-implant/gingival sulcus until mild resistance was felt and held for 30 sec. Care was taken to avoid mechanical trauma when placing the strips and those strips contaminated with blood were discarded. The strips were stored in Eppendorf tubes (Eppendorf, Hamburg, Germany) at -80C until further processed.

Proteomic analysis of crevicular fluid samples (PICF/GCF) The PICF and GCF samples collected from the study implant sites (n=10) and the control tooth sites (n=10), respectively at T0 and T1 were pooled and used for proteomics analysis. In brief, 20 µg of total protein per pooled sample were reduced, alkylated, trypsinized, and purified with single-pot, solid-phase-enhanced sample preparation (SP3) assisted protein digestion using the PreOmics' SP3-iST (PreOmics GmbH) following the manufacturing protocol for protein extraction and digestion. These extracts were concentrated using a Speedvac (Thermo Savant SPD121P, Thermo Scientific, Waltham, MA, USA) and stored at -20 °C until further use.

The digested samples were first reconstituted with 30 µL of 3% acetonitrile (ACN) in 0.1% formic acid then subjected to Fusion Orbitrap Lumos mass spectrometer (Thermo Fisher Scientific) interfaced to an Easy nano-flow HPLC system (Thermo Fisher Scientific) for proteomics analysis. During proteomics analysis, a three-liner gradient of acetonitrile and water was used with 0.1% formic acid at a 300 nL/minute flow rate. The gradient progressed from 2% to 30% acetonitrile over 60 minutes, then from 30% to 97% acetonitrile in 10 minutes, and finally held at 97% acetonitrile for 10 minutes. The mass spectrometer was set to operate in a data-dependent manner, automatically switching between MS and MS/MS using the Xcalibur software package from Thermo Fisher Scientific. A mass range of 300-1500 m/z was selected for the Orbitrap analyzer.

The acquired MS data were processed using the Mascot (version 2.4.1, Matrix Science) search engine against an in-house database containing 10,125,458 entries, which included human (accessed on 22nd February 2022 from Uniprot) and bacterial (accessed on 22nd February 2022 from eHOMD) proteins, common MS contaminants, and reverse sequences for estimating the false discovery rate. During the proteomics analysis, the precursor ion tolerance and fragment ion tolerance were set to 10 ppm and ±0.6 Da, respectively. Up to two missed cleavages per peptide were allowed for tryptic digestion. The carbamidomethylation modification on cysteine was selected as a fixed modification, while deamidation of asparagine and glutamine and oxidation of methionine were chosen as variable modification parameters.

The spectrum reports of the search results were generated using Scaffold software (version 4.2.1, Proteome software), and proteins with FDR at 1%, minimal 2 unique peptides identified, as peptide FDR at 0.1% were used for relative protein abundance analysis. Fold changes in abundance intensity were calculated based on value log2 fold change (FC) between pairs of consecutive time points using R-software (R: A Language and Environment for Statistical Computing, R Development Core Team). Proteins with a log2FC ≥ 1 of unique spectrum counts between two conditions or exclusively identified in one condition were considered regulated.

Bioinformatics analysis for the regulated proteins The regulated proteins underwent overrepresentation analysis (ORA) against the Hallmark database using the WebGestalt online tool. The analysis, conducted on March 25th, 2022, aimed to compare the regulation of proteins in teeth and implants between T0 and T1 conditions. Similarly, on March 29th, 2022, the analysis examined the regulation of proteins in both teeth and implants under either the T0 or T1 conditions. The top 10 enriched results, ranked by p-value using the hypergeometric distribution, were reported. However, only pathways with a p-value < 0.05 were considered as regulated.

Being tested
Plaque control
Keywords
Peri-implant tissue, tissue remodeling, first year of function, proteomics, crevicular fluid, periodontal parametres
Medical subject headings
Peri-Implantitis, Periodontal Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Plaque controlBehavioural

    Subjects are motivated for optimal oral hygiene

Study groups in NCT06379022
Study groupRoleWhat they receive
Implant unitNewly restored single implant that is closely followed for plaque control
Receives: Behavioral: Plaque control
Tooth unitA contralateral tooth that is closely followed for plaque control
Receives: Behavioral: Plaque control

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Probing pocket depth

    Assessed by a periodontal probe

    Measured: baseline and 12 months

  2. Protein expression

    proteomic analysis

    Measured: baseline and 12 months

Secondary outcomes (3)
  1. Recession

    Assessed by a periodontal probe

    Measured: baseline and 12 months

  2. Bleeding upon probing

    Assessed after probing teh crevice

    Measured: baseline and 12 months

  3. Inflammation index

    Assessed visually

    Measured: baseline and 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Apr 2024
  2. Study start3 Dec 2018
  3. Primary completion29 Nov 2019
  4. Study completion29 Nov 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
10 participants (actual)
Target duration
12 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT06379022
Sponsor's protocol ID
AUTh-29/21-11-2018
Status last verified
Apr 2024
First submitted
18 Apr 2024
Last updated
23 Apr 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Available upon request

Publications

  • Apatzidou DA, Violesti A, Konstantinidis A, Bao K, Silbereisen A, Bostanci N. Protein profile at newly restored implants compared to contralateral teeth over 12-months: a pilot study. Clin Oral Investig. 2024 Oct 11;28(11):590. doi: 10.1007/s00784-024-05984-w.

    PubMed 39390228

Questions about this trial

What is this clinical trial studying?

An observational study of Peri-Implantitis and Peri-implant Mucositis, run by Aristotle University Of Thessaloniki at 1 site in Greece.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Probing pocket depth (time frame: baseline and 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06379022, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in